Evidence map›Paper›PMID 37511471›Full record

ReviewInternational journal of molecular sciences2023

Antibiotic Resistance, Susceptibility Testing and Stewardship in

Ho-Yu Ng, Wai K Leung, Ka-Shing Cheung

Registry-linked trialAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06318104 (Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06318104 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Efficacy and Safety of a Triple Eradication Scheme for Helicobacter Pylori Based on Amoxicillin 1g + Clarithromycin 500 mg and Tegoprazan 50 mg vs Amoxicillin 1g + Clarithromycin 500 mg and Esomeprazole 40 mg Twice a Day for 14 Days

TypeinterventionalSponsorHospital General de México Dr. Eduardo LiceagaRan2024 to 2025Enrolled160ConditionsHelicobacter Pylori InfectionArmsTegoprazan, Esomeprazole 40mg
3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Review
  2. Antibiotics (Basel, Switzerland) · 2026
    Review
  3. Article
  4. New Insights into CRISPR-like Arrays inPathogens (Basel, Switzerland) · 2026
    Article
  5. Article
  6. [Study on the Inhibitory Effect and Mechanism of Trans-2-Decenal onSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Article
  7. Article
  8. Article
  9. Resistance to Clarithromycin and Fluoroquinolones inAntibiotics (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Effect of nonsurgical periodontal therapy on the eradication of gastricJournal of advanced periodontology & implant dentistry · 2025
    Article
  12. Article
  13. Diagnosis and treatment ofFuture microbiology · 2025
    Review
  14. Antibiotic Resistance and Genetic Determinants ofInternational journal of molecular sciences · 2025
    Article
  15. Review
  16. Antibiotics (Basel, Switzerland) · 2025
    Review
  17. Overcoming antibiotic-resistantWorld journal of gastroenterology · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ho-Yu NgSchool of Clinical Medicine, The University of Hong Kong, Hong Kong, China.
Wai K LeungDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.ORCID 0000-0002-5993-1059
Ka-Shing CheungDepartment of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, China.ORCID 0000-0002-4838-378X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the declining trend of

Indexed as

Helicobacter InfectionsHelicobacter pyloriAnti-Bacterial AgentsClarithromycinDrug Resistance, BacterialDrug Therapy, CombinationHumansAnti-Bacterial AgentsClarithromycinbismuthH. pylorinext generation sequencingNGSstool based-PCRvonoprazan

Identifiers

PMID37511471
PMCPMC10380565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.